LAUSR

Bladder cancer (BCa) is the secondmost common genitourinarymaCOL10A1, DKK2, HIST2H3D and MMP11) that were significantly correlignancywith 81,190 estimated new diagnosis in the 2018 in the United States only (Siegel et al., 2018). Radical cystectomy (RC) with bilateral pelvic node dissection (PLND) represents the gold standard for muscle invasive BCa and for very recurrent high risk non-muscle invasive tumors (Alfred Witjes et al., n.d.). Lymph node metastases are the pathologic features with the greater impact on mortality at RC and are diagnosed in around 18.0–30.4% patients affected by localized BCa (Stein et al., 2001). However, cross-sectional imaging can only partially predict preoperatively the presence of nodemetastases (Moschini et al., n.d.). In this regard, after decades without improvements in the field of BCa, several progresses in the last few years are improving patients and tumor classifications, starting a new era of precision medicine in urooncology. In this issue of EBioMedicine, Wu et al. (Wu et al., 2018) report a genomic-clinicopathologic nomogram for the preoperative identification of BCa patients affected by lymph node metastases. Authors used amodel to identify mRNAs correlatedwith the presence of nodemetastases and developed a clinical nomogram integrating clinical and pathological variables. They identified five different mRNAs (ADRA1D,